NCT00413634 - The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2006

Primary Completion Date

January 22, 2008

Study Completion Date

January 22, 2008

Conditions

Essential Thrombocythaemia

Interventions

DRUG

anagrelide hydrochloride

Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.

DRUG

anagrelide hydrochloride

Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.

Trial Locations (5)

75185

Uppsala Akademiska Sjukhus, Uppsala

Unknown

Hospitl Del Mar, Barcelona

Quintiles Hermelinen, Luleå

Quintiles AB Phase I Unit, Uppsala

Belfast City Hospital, Belfast